Gurevich, Irina http://orcid.org/0000-0001-9576-0456
Agarwal, Pooja
Zhang, PeiPei http://orcid.org/0000-0003-0918-0610
Dolorito, John A.
Oliver, Stacie
Liu, Henry
Reitze, Nicholas
Sarma, Nikhil
Bagci, Isin Sinem
Sridhar, Kunju
Kakarla, Visesha
Yenamandra, Vamsi K.
O’Malley, Mark http://orcid.org/0000-0002-5463-977X
Prisco, Marco
Tufa, Sara F. http://orcid.org/0000-0002-6447-8041
Keene, Douglas R.
South, Andrew P. http://orcid.org/0000-0001-7650-0835
Krishnan, Suma M.
Marinkovich, M. Peter http://orcid.org/0000-0001-5528-8046
Funding for this research was provided by:
U.S. Department of Veterans Affairs
Article History
Received: 26 April 2021
Accepted: 8 February 2022
First Online: 28 March 2022
Competing interests
: M.P.M. received funding from Krystal Biotech to conduct this study through a sponsored research award administered through the Stanford University Office of Research Management. M.P.M. is also an investigator for the following companies that are studying molecular corrective therapies for recessive dystrophic epidermolysis bullosa: Castle Creek Pharmaceuticals, Abeona Therapeutics, WINGS therapeutics and Phoenix Tissue Repair. A.P.S. owns stock in Krystal Biotech. P.A., P.P.Z. and S.O., as well as H.L., N.R., N.S., M.O. and S.M.K. are employees of Krystal Biotech. All other authors have no competing interests.